Article No
AG-25B-0005-C100
anti-NLRP1/NALP1 (human), pAb (AL176)
anti-NLRP1/NALP1 (human), pAb (AL176)
Antibodies Primary
Specifications
| Application | IHC, WB |
| Article No | AG-25B-0005-C100 |
| Country Availability | SE, FI, DK, NO, IS, EE, LV, LT |
| Clone | polyclonal |
| Clone Type | polyclonal |
| Concentration | 1 mg/ml |
| Conjugation | Unconjugated |
| Description | anti-NLRP1/NALP1 (human), pAb (AL176) |
| Supplier | Adipogen Life Sciences |
| Entrez Gene ID | 22861 |
| Format | Liquid |
| Gene Symbol | NLRP1 |
| Immunogen | Synthetic peptide corresponding to aa 2-25 (A2GGAWGRLACYLEFLKKEELKEFQ25) at the N-terminus of human NLRP1/NALP1. |
| Notes | NALP1/NLRP1 is able to form cytoplasmic structures termed death effector filaments. It enhances and stimulates apoptosis through activation of different caspase cascades. It is involved in the activation of caspase-1 and caspase-5 as part of the NALP1 inflammasome complex which leads to processing and release of IL1B and IL18. Genetic variations in the NLRP1/NALP1 gene are associated with susceptibility to vitiligo-associated multiple autoimmune disease type 1, an autoimmune disorder characterized by the association of vitiligo with several autoimmune and autoinflammatory diseases including autoimmune thyroid disease, rheumatoid arthritis and systemic lupus erythematosus.|Polyclonal Antibody. Recognizes human NLRP1/NALP1. Does not cross-react with mouse NLRP1/NALP1. Source: Rabbit. Applications: WB. Liquid. In PBS containing 10% glycerol and 0.02% sodium azide. NALP1/NLRP1 is able to form cytoplasmic structures termed death effector filaments. It enhances and stimulates apoptosis through activation of different caspase cascades. It is involved in the activation of caspase-1 and caspase-5 as part of the NALP1 inflammasome complex which leads to processing and release of IL1B and IL18. Genetic variations in the NLRP1/NALP1 gene are associated with susceptibility to vitiligo-associated multiple autoimmune disease type 1, an autoimmune disorder characterized by the association of vitiligo with several autoimmune and autoinflammatory diseases including autoimmune thyroid disease, rheumatoid arthritis and systemic lupus erythematosus. |
| Alias Names | NACHT-, LRR- and PYD-containing Protein 1; NLRP1; Caspase Recruitment Domain-containing Protein 7; Death Effector Filament-forming Ced-4-like Apoptosis Protein; Nucleotide-binding Domain and Caspase Recruitment Domain |
| Product Type | Antibodies Primary |
| Research area | Inflammation |
| Shipping Information | BLUE ICE |
| Size | 100 ug |
| Source / Host | rabbit |
| Species Reactivity | human |
| Stability | Stable for at least 1 year after receipt when stored at -20°C. |
| Storage | -20°C, 4°C |
| Substrate / Buffer | Liquid. In PBS containing 10% glycerol and 0.02% sodium azide. |
| Technical Specifications | Polyclonal Antibody. Recognizes human NLRP1/NALP1. Does not cross-react with mouse NLRP1/NALP1. Source: Rabbit. Applications: WB. Liquid. In PBS containing 10% glycerol and 0.02% sodium azide. NALP1/NLRP1 is able to form cytoplasmic structures termed death effector filaments. It enhances and stimulates apoptosis through activation of different caspase cascades. It is involved in the activation of caspase-1 and caspase-5 as part of the NALP1 inflammasome complex which leads to processing and release of IL1B and IL18. Genetic variations in the NLRP1/NALP1 gene are associated with susceptibility to vitiligo-associated multiple autoimmune disease type 1, an autoimmune disorder characterized by the association of vitiligo with several autoimmune and autoinflammatory diseases including autoimmune thyroid disease, rheumatoid arthritis and systemic lupus erythematosus. |
| UniProt Number | Q9C000 |
| Product Page Updated | 2024-02-01T08:25:01.492Z |
